Chokri Ben Lamine: Strategic Decision Making in Hematology under Competing Risks
Chokri Ben Lamine, Adult Hematology and SCT Assistant Consultant at Oncology Center of Excellence at King Faisal Specialist Hospital and Research Center, shared a post on X:
“Game theory in Hematology equals strategic decision-making under competing risks (disease vs toxicity vs cost vs time).
Core idea: optimize outcome when multiple players (tumor, host, physician, system) interact․
AML induction vs wait
- aggressive disease equals ‘move early’ (dominant strategy)
- frail pt equals delay/low-intensity leads to minimize loss (minimax)․
MRD-guided decisions
- MRD positive leads to escalate (allo-SCT)
- MRD negative leads to de-escalate
- dynamic strategy equals sequential game․
CAR-T vs bispecific vs SCT
- competing strategies with different payoffs (CR, toxicity, durability)
- choose based on patient fitness plus tumor biology leads to expected utility maximization․
GVHD vs GVL balance
- immunosuppression decrease GVHD but increase relapse
- optimal point equals Nash equilibrium between immune control and toxicity․
Anticoagulation in cancer thrombosis
- bleeding risk vs clot risk
- adjust dose/timing leads to risk-dominant strategy․
Transfusion thresholds (PBM)
- liberal vs restrictive
- restrictive often ‘dominant strategy’ leads to same outcomes, fewer risks․
Antibiotic use in FN
- overuse leads to resistance
- underuse leads to mortality
- stewardship equals repeated game with system-level payoff․
Clonal evolution (AML/CLL/MM)
- tumor adapts to therapy equals ‘evolutionary game’
- combination/sequencing prevents resistant clone dominance․
Resource allocation (ICU beds, CAR-T slots)
- prioritize pts with highest benefit probability
- utility plus fairness balance․
One-liner
Hematology decisions equals multi-step strategic games leads to best outcomes when timing, sequencing, and risk trade-offs are optimized.”
Stay updated with Hemostasis Today.
-
Mar 30, 2026, 14:10Erwin Loh: Primary Prevention of Cardiovascular Events With Evolocumab in High-Risk Patients With Diabetes
-
Mar 30, 2026, 13:59David McIntosh: How European Plasma Policy Shapes Global Access to Life-Saving Therapies
-
Mar 30, 2026, 13:27Stephanie A. Haddad: Improving Access in Fertility Preservation for AYA Hematology/Oncology Patients
-
Mar 29, 2026, 16:17Ammara Mushtaq: How Research Fills the Gaps in Fast Paced Healthcare
-
Mar 29, 2026, 16:16Pete Stibbs: Insights from the 32nd World Congress of the International Union of Angiology
-
Mar 29, 2026, 16:15Davide Capodanno: Independent Investigators Lead the First Head to Head DOAC Comparison
-
Mar 29, 2026, 16:14James Crowley: Fibrosis Can Be Caused by Mechanical Disruption of the Lymphatic Vessels Alone
-
Mar 29, 2026, 16:02Omar Adwan: Understanding Clinical Significance and Diagnostic Implications of Acanthocytes
-
Mar 29, 2026, 16:01Ifeanyichukwu Ifechidere: Direct Oral Anticoagulants Broke Traditional Coag Testing